Shockwave CS Guide Catheter

K243757 · Shockwave Medical, Inc. · DQY · May 2, 2025 · Cardiovascular

Device Facts

Record IDK243757
Device NameShockwave CS Guide Catheter
ApplicantShockwave Medical, Inc.
Product CodeDQY · Cardiovascular
Decision DateMay 2, 2025
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 870.1250
Device ClassClass 2

Intended Use

The Shockwave CS Guide Catheter is intended to access the coronary venous system and may be used alone (9F) or in a dual catheter delivery (e.g., 9F with 7F). The catheter serves as a conduit for the introduction of interventional/diagnostic devices introduced into the coronary venous system.

Device Story

The Shockwave CS Guide Catheter is a single-lumen percutaneous catheter used to access the coronary venous system. It functions as a conduit for introducing interventional or diagnostic devices. The device features a PTFE liner, stainless steel braid, and polymer outer jacket, with a curved distal shaft and radiopaque tip for visualization. A proximal luer fitting connects to a hemostasis valve and includes a curve indicator for tactile and visual orientation. Used in clinical settings by physicians, the catheter facilitates the placement of other devices within the coronary venous system. It is provided EO sterile for single use. By providing a stable pathway, it assists clinicians in performing venous interventions, potentially improving procedural efficiency and patient outcomes.

Clinical Evidence

Bench testing only. Testing included biocompatibility (cytotoxicity, hemocompatibility, sensitization, irritation, acute systemic toxicity, materials-mediated pyrogenicity), visual inspection, dimensional analysis, particulate evaluation, leak testing, bond strength, torque strength, flexibility/kink resistance, corrosion resistance, luer functionality, catheter compatibility, radiopacity, and shelf-life verification. Packaging met ISO 11607-1 requirements. Sterilization validated to SAL 10^-6 per ISO 11135.

Technological Characteristics

Single-lumen catheter; PTFE liner, stainless steel braid, polymer outer jacket. Features curved distal shaft, radiopaque tip, and proximal luer fitting with curve indicator. Sterilized via ethylene oxide (EO) per ISO 11135. Biocompatibility per ISO 10993-1. Mechanical properties include torque strength, flexibility, and kink resistance.

Indications for Use

Indicated for accessing the coronary venous system to serve as a conduit for the introduction of interventional or diagnostic devices in patients requiring such procedures.

Regulatory Classification

Identification

A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0} FDA U.S. FOOD & DRUG ADMINISTRATION May 2, 2025 Shockwave Medical, Inc. Renee Maack Principal Regulatory Affairs Specialist 5403 Betsy Ross Drive Santa Clara, California 95054 Re: K243757 Trade/Device Name: Shockwave CS Guide Catheter Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous catheter Regulatory Class: Class II Product Code: DQY Dated: April 4, 2025 Received: April 4, 2025 Dear Renee Maack: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K243757 - Renee Maack Page 2 Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, {2} K243757 - Renee Maack Page 3 LYDIA S. GLAW -S Digitally signed by LYDIA S. GLAW -S Date: 2025.05.02 17:31:41 -04'00' Lydia Glaw Assistant Director DHT2C: Division of Coronary and Peripheral Intervention Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} FORM FDA 3881 (6/20) Page 1 of 1 PSC Publishing Services (301) 443-6740 EF | DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below. | | --- | --- | | 510(k) Number (if known) K243757 | | | Device Name Shockwave CS Guide Catheter | | | Indications for Use (Describe) The Shockwave CS Guide Catheter is intended to access the coronary venous system and may be used alone (9F) or in a dual catheter delivery (e.g., 9F with 7F). The catheter serves as a conduit for the introduction of interventional/diagnostic devices introduced into the coronary venous system. | | | Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | | | CONTINUE ON A SEPARATE PAGE IF NEEDED. | | | This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | | | The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov | | | "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | | {4} K243757 # 510(k) Summary This 510(k) Summary is submitted in accordance with the requirements of the Safe Medical Devices Act (SMDA) of 1990 and 21 CFR 807.92. I. SUBMITTER Shockwave Medical, Inc. 5403 Betsy Ross Drive Santa Clara, CA 95054 Phone: 877-775-4846 Contact Person: Renee Maack Date Prepared: April 3, 2025 II. DEVICE Name of Device: Shockwave CS Guide Catheter Common Name: Guide Catheter Classification Name: Catheter, percutaneous Class: II Product Code: DQY III. PREDICATE Boston Scientific Acuity Pro Lead Delivery System (K171612) IV. DEVICE DESCRIPTION The Shockwave CS Guide Catheter is a single lumen catheter consisting of a PTFE liner, stainless steel braid, and polymer outer jacket. The transition segments of the catheter have a gradual decrease in stiffness starting from the proximal shaft segment and ending at the distal tip. The Shockwave CS Guide Catheter features a curved distal shaft with radiopaque tip. The proximal end of the guide catheter has a standard luer fitting for connecting to a hemostasis valve. The proximal luer also includes a curve indicator to match the direction of the guide catheter tip curvature and provides a tactile and visual cue to the user. The Shockwave CS Guide Catheter is provided EO sterile and is for single use only. V. INDICATIONS FOR USE The Shockwave CS Guide Catheter is intended to access the coronary venous system and may be used alone (9F) or in a dual catheter delivery (e.g., 9F with 7F). The catheter serves as a conduit for the introduction of interventional/diagnostic devices introduced into the coronary venous system. VI. INDICATIONS FOR USE COMPARISON Both the subject and predicate device have the same intended use as a conduit for the introduction devices into the coronary venous system. While the Indications for Use statement for the subject device is not identical to the predicate device, the differences do not alter the intended use of the device, nor do they affect the safety and effectiveness of the device relative to the predicate and support substantial equivalence. VII. TECHNOLOGICAL COMPARISON The subject and predicate device are percutaneous catheter systems designed to facilitate access and placement of devices within the coronary venous system. A comparison of the intended use and technological characteristics demonstrates that the Shockwave CS Guide Catheter is substantially equivalent to the Boston Scientific Acuity Pro (K171612). The minor differences do not raise new questions for safety and effectiveness. The Shockwave CS Guide Catheter and Boston Acuity Pro Catheter have the same intended use and sterilization method. They have similar design features such as a radiopaque tip and guidewire compatibility. The Shockwave CS Guide Catheter and Boston Acuity Pro Catheter are equivalent in {5} terms of principle of operation. There are minor differences in design of the proximal end, as the Shockwave CS Guide Catheter does not have an integrated hub requiring a venous access dilator. The Shockwave CS Guide Catheter and Cordis Vista Brite Tip (reference device) have the same intended uses and sterilization methods. They have similar design features such as a radiopaque tip and a proximal luer fitting for connecting to a hemostasis valve and are compatible with guidewires. There are minor differences in design of the distal end, as the Shockwave CS Guide Catheter has a pre-curved distal section and the Cordis Vista Brite Tip has a straight distal end. ## VIII. SUBSTANTIAL EQUIVALENCE The following performance testing was performed to demonstrate the device is substantially equivalent to the predicate device, meets its design specification and is as safe and effective as the predicate device. ## Biocompatibility The biocompatibility evaluation of the Shockwave CS Guide Catheter was conducted in accordance with ISO 10993-1 Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process. The device is considered an external communicating device with limited (≤24 hour) contact with circulating blood; therefore, evaluation was conducted in the following categories: - Cytotoxicity - Hemocompatibility - Sensitization - Irritation - Acute Systemic Toxicity - Materials-Mediated Pyrogenicity ## Design Verification The following bench testing was conducted to demonstrate that the Shockwave CS Guide Catheter met all performance specifications: - Visual inspection - Device dimensions - Particulate evaluation - Freedom from Liquid and Air Leakage - Bond Strength - Torque Strength - Flexibility and Kink Resistance - Corrosion Resistance - Luer Functionality - Catheter compatibility - Radiopacity - Shelf-life verification ## Sterilization The Shockwave CS Guide Catheter is intended for single use only and is provided sterile via ethylene oxide (EO) gas to achieve a Sterility Assurance Level (SAL) of $10^{-6}$ per ISO 11135. ## Packaging Packaging verification studies were performed in compliance with the applicable requirements of ISO 11607-1. All device packaging met acceptance criteria following 2X sterilization, environmental conditioning, and transport simulation. {6} IX. CONCLUSION Substantial equivalence is demonstrated between the subject device and the predicate device through similar technological characteristics and indications/intended use. There are no differences between the subject device and the predicate that raise new questions for safety and effectiveness. The successful completion of non-clinical testing demonstrates that the Shockwave CS Guide Catheter performs as intended and is substantially equivalent to the predicate. 3
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...